Latest filings (excl ownership)
S-3/A
Shelf registration (amended)
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
D
$18.37 mm in options / securities to be acquired, sold $18.37 mm, 4 investors
29 Mar 24
S-3
Shelf registration
28 Mar 24
S-3
Shelf registration
28 Mar 24
8-K
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Other Events
28 Mar 24
424B5
Prospectus supplement for primary offering
18 Mar 24
8-K
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
15 Mar 24
8-K
Other Events
11 Mar 24
8-K
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
8 Mar 24
8-K
Other Events
5 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Feb 24
S-8
Registration of securities for employees
19 Jan 24
8-K
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
8 Jan 24
424B5
Prospectus supplement for primary offering
5 Jan 24
424B5
Prospectus supplement for primary offering
3 Jan 24
8-K
Termination of a Material Definitive Agreement
3 Jan 24
8-K
Other Events
22 Dec 23
8-K
Entry into a Material Definitive Agreement
13 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Dec 23
8-K
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2023 Financial Results
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
424B5
Prospectus supplement for primary offering
1 Nov 23
8-K
SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
31 Oct 23
8-K
SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia
16 Oct 23
8-K
SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia
13 Oct 23
8-K
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results
10 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
20 Jun 23
8-K
Regulation FD Disclosure
1 Jun 23
8-K
SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
PRE 14A
Preliminary proxy
17 Apr 23
S-8
Registration of securities for employees
16 Mar 23
Latest ownership filings
SC 13G
HIGHBRIDGE CAPITAL MANAGEMENT LLC
7 Feb 24
4
Angelos M. Stergiou
25 Jan 24
4
DAVID A SCHEINBERG
25 Jan 24
4
BARBARA A WOOD
25 Jan 24
4
Katherine Bach Kalin
25 Jan 24
4
Jane Wasman
25 Jan 24
4
Robert Francomano
25 Jan 24
4
John Varian
25 Jan 24
4
NOSTRAND ROBERT L VAN
25 Jan 24
4
John Thomas Burns
25 Jan 24
4
BARBARA A WOOD
8 Dec 23
4
Angelos M. Stergiou
8 Dec 23
4
Robert Francomano
8 Dec 23
4
John Thomas Burns
8 Dec 23
4
BARBARA A WOOD
3 Feb 23
4
John Thomas Burns
3 Feb 23
4
Angelos M. Stergiou
3 Feb 23
4
Robert Francomano
3 Feb 23
4
John Varian
3 Feb 23
4
Jane Wasman
3 Feb 23
4
NOSTRAND ROBERT L VAN
3 Feb 23
4
DAVID A SCHEINBERG
3 Feb 23
4
Katherine Bach Kalin
3 Feb 23
4
Angelos M. Stergiou
5 Dec 22
4
John Thomas Burns
5 Dec 22
4
BARBARA A WOOD
5 Dec 22
4
Katherine Bach Kalin
16 Aug 22
3
Katherine Bach Kalin
16 Aug 22
4
Robert Francomano
15 Mar 22
3
Robert Francomano
14 Mar 22
4
BARBARA A WOOD
1 Feb 22
4
Jane Wasman
1 Feb 22
4
John Varian
1 Feb 22
4
NOSTRAND ROBERT L VAN
1 Feb 22
4
Angelos M. Stergiou
1 Feb 22
4
DAVID A SCHEINBERG
1 Feb 22
4
John Thomas Burns
1 Feb 22
4
Angelos M. Stergiou
3 Dec 21
4
BARBARA A WOOD
3 Dec 21
4
John Thomas Burns
3 Dec 21